
Shawn R Lockhart

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4494439/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clinical Infectious Diseases, 2020, 71, 1367-1376.	5.8	1,429
2	Simultaneous Emergence of Multidrug-Resistant <i>Candida auris</i> on 3 Continents Confirmed by Whole-Genome Sequencing and Epidemiological Analyses. Clinical Infectious Diseases, 2017, 64, 134-140.	5.8	1,099
3	Changes in the epidemiological landscape of invasive candidiasis. Journal of Antimicrobial Chemotherapy, 2018, 73, i4-i13.	3.0	349
4	Fluconazole resistance in Candida species: a current perspective. Infection and Drug Resistance, 2017, Volume 10, 237-245.	2.7	346
5	Antimicrobial Resistance among Gram-Negative Bacilli Causing Infections in Intensive Care Unit Patients in the United States between 1993 and 2004. Journal of Clinical Microbiology, 2007, 45, 3352-3359.	3.9	310
6	Changes in Incidence and Antifungal Drug Resistance in Candidemia: Results From Population-Based Laboratory Surveillance in Atlanta and Baltimore, 2008-2011. Clinical Infectious Diseases, 2012, 55, 1352-1361.	5.8	307
7	Necrotizing Cutaneous Mucormycosis after a Tornado in Joplin, Missouri, in 2011. New England Journal of Medicine, 2012, 367, 2214-2225.	27.0	297
8	Declining Incidence of Candidemia and the Shifting Epidemiology of Candida Resistance in Two US Metropolitan Areas, 2008–2013: Results from Population-Based Surveillance. PLoS ONE, 2015, 10, e0120452.	2.5	235
9	Prevalent mutator genotype identified in fungal pathogen Candida glabrata promotes multi-drug resistance. Nature Communications, 2016, 7, 11128.	12.8	227
10	Species Identification and Antifungal Susceptibility Testing of Candida Bloodstream Isolates from Population-Based Surveillance Studies in Two U.S. Cities from 2008 to 2011. Journal of Clinical Microbiology, 2012, 50, 3435-3442.	3.9	225
11	Tracing the Evolutionary History and Global Expansion of Candida auris Using Population Genomic Analyses. MBio, 2020, 11, .	4.1	224
12	In <i>Candida albicans</i> , White-Opaque Switchers Are Homozygous for Mating Type. Genetics, 2002, 162, 737-745.	2.9	217
13	Azole Resistance in Aspergillus fumigatus Isolates from the ARTEMIS Global Surveillance Study Is Primarily Due to the TR/L98H Mutation in the <i>cyp51A</i> Gene. Antimicrobial Agents and Chemotherapy, 2011, 55, 4465-4468.	3.2	211
14	Multiple introductions and subsequent transmission of multidrug-resistant Candida auris in the USA: a molecular epidemiological survey. Lancet Infectious Diseases, The, 2018, 18, 1377-1384.	9.1	204
15	Investigation of the First Seven Reported Cases of <i>Candida auris,</i> a Globally Emerging Invasive, Multidrug-Resistant Fungus — United States, May 2013–August 2016. Morbidity and Mortality Weekly Report, 2016, 65, 1234-1237.	15.1	201
16	Role of FKS Mutations in Candida glabrata: MIC Values, Echinocandin Resistance, and Multidrug Resistance. Antimicrobial Agents and Chemotherapy, 2014, 58, 4690-4696.	3.2	182
17	Geographic Distribution and Antifungal Susceptibility of the Newly Described Species <i>Candida orthopsilosis</i> and <i>Candida metapsilosis</i> in Comparison to the Closely Related Species <i>Candida parapsilosis</i> . Journal of Clinical Microbiology, 2008, 46, 2659-2664.	3.9	176
18	Opaque cells signal white cells to form biofilms in Candida albicans. EMBO Journal, 2006, 25, 2240-2252.	7.8	155

#	Article	IF	CITATIONS
19	Rapid and Accurate Molecular Identification of the Emerging Multidrug-Resistant Pathogen Candida auris. Journal of Clinical Microbiology, 2017, 55, 2445-2452.	3.9	140
20	Antifungal Susceptibility Testing: Current Approaches. Clinical Microbiology Reviews, 2020, 33, .	13.6	138
21	Epidemiology and Risk Factors for Echinocandin Nonsusceptible Candida glabrata Bloodstream Infections: Data From a Large Multisite Population-Based Candidemia Surveillance Program, 2008–2014. Open Forum Infectious Diseases, 2015, 2, ofv163.	0.9	135
22	Cell Biology of Mating in Candida albicans. Eukaryotic Cell, 2003, 2, 49-61.	3.4	132
23	Molecular Epidemiology of Candida auris in Colombia Reveals a Highly Related, Countrywide Colonization With Regional Patterns in Amphotericin B Resistance. Clinical Infectious Diseases, 2019, 68, 15-21.	5.8	132
24	Cryptococcus gattii in North American Pacific Northwest: Whole-Population Genome Analysis Provides Insights into Species Evolution and Dispersal. MBio, 2014, 5, e01464-14.	4.1	126
25	Notes from the Field: Ongoing Transmission of <i>Candida auris</i> in Health Care Facilities — United States, June 2016–May 2017. Morbidity and Mortality Weekly Report, 2017, 66, 514-515.	15.1	124
26	Skin Facilitates <i>Candida albicans</i> Mating. Infection and Immunity, 2003, 71, 4970-4976.	2.2	122
27	<i>FKS</i> Mutations and Elevated Echinocandin MIC Values among <i>Candida glabrata</i> Isolates from U.S. Population-Based Surveillance. Antimicrobial Agents and Chemotherapy, 2010, 54, 5042-5047.	3.2	119
28	Triazole resistance surveillance in Aspergillus fumigatus. Medical Mycology, 2018, 56, S83-S92.	0.7	114
29	The Closely Related Species Candida albicans and Candida dubliniensis Can Mate. Eukaryotic Cell, 2004, 3, 1015-1027.	3.4	112
30	Candida auris and multidrug resistance: Defining the new normal. Fungal Genetics and Biology, 2019, 131, 103243.	2.1	112
31	Population-Based Active Surveillance for Culture-Confirmed Candidemia — Four Sites, United States, 2012–2016. MMWR Surveillance Summaries, 2019, 68, 1-15.	34.6	111
32	Release of a Potent Polymorphonuclear Leukocyte Chemoattractant Is Regulated by White-Opaque Switching in Candida albicans. Infection and Immunity, 2004, 72, 667-677.	2.2	110
33	Emergence of azole-resistant <i>Candida parapsilosis</i> causing bloodstream infection: results from laboratory-based sentinel surveillance in South Africa. Journal of Antimicrobial Chemotherapy, 2016, 71, 1994-2004.	3.0	110
34	An integrated genomic and transcriptomic survey of mucormycosis-causing fungi. Nature Communications, 2016, 7, 12218.	12.8	103
35	On the Origins of a Species: What Might Explain the Rise of Candida auris?. Journal of Fungi (Basel,) Tj ETQq1 1	0.784314	rgBT /Overloc 103
36	α-Pheromone-Induced "Shmooing―and Gene Regulation Require White-Opaque Switching during Candida albicans Mating. Eukaryotic Cell, 2003, 2, 847-855.	3.4	102

#	Article	IF	CITATIONS
37	Mutations in <i>TAC1B</i> : a Novel Genetic Determinant of Clinical Fluconazole Resistance in Candida auris. MBio, 2020, 11, .	4.1	101
38	Emerging and reemerging fungal infections. Seminars in Diagnostic Pathology, 2019, 36, 177-181.	1.5	100
39	Management of Cryptococcus gattii meningoencephalitis. Lancet Infectious Diseases, The, 2015, 15, 348-355.	9.1	98
40	Correlation of Genotype and <i>In Vitro</i> Susceptibilities of <i>Cryptococcus gattii</i> Strains from the Pacific Northwest of the United States. Journal of Clinical Microbiology, 2010, 48, 539-544.	3.9	95
41	Transmission of Cryptococcus neoformans by Organ Transplantation. Clinical Infectious Diseases, 2011, 52, e94-e98.	5.8	93
42	Heterozygosity of genes on the sex chromosome regulatesCandida albicansvirulence. Molecular Microbiology, 2007, 64, 1587-1604.	2.5	91
43	<i>Lodderomyces elongisporus</i> Masquerading as <i>Candida parapsilosis</i> as a Cause of Bloodstream Infections. Journal of Clinical Microbiology, 2008, 46, 374-376.	3.9	89
44	Identification of Candida nivariensis and Candida bracarensis in a Large Global Collection of Candida glabrata Isolates: Comparison to the Literature. Journal of Clinical Microbiology, 2009, 47, 1216-1217.	3.9	87
45	Molecular Mechanisms of Fluconazole Resistance in Candida parapsilosis Isolates from a U.S. Surveillance System. Antimicrobial Agents and Chemotherapy, 2015, 59, 1030-1037.	3.2	87
46	Candida auris for the Clinical Microbiology Laboratory: Not Your Grandfather's Candida Species. Clinical Microbiology Newsletter, 2017, 39, 99-103.	0.7	86
47	Ca3 Fingerprinting of Candida albicans Isolates from Human Immunodeficiency Virus-Positive and Healthy Individuals Reveals a New Clade in South Africa. Journal of Clinical Microbiology, 2002, 40, 826-836.	3.9	85
48	Activity of CD101, a long-acting echinocandin, against clinical isolates of Candida auris. Diagnostic Microbiology and Infectious Disease, 2018, 90, 196-197.	1.8	82
49	The NDV-3A vaccine protects mice from multidrug resistant Candida auris infection. PLoS Pathogens, 2019, 15, e1007460.	4.7	82
50	Methodologies for in vitro and in vivo evaluation of efficacy of antifungal and antibiofilm agents and surface coatings against fungal biofilms. Microbial Cell, 2018, 5, 300-326.	3.2	81
51	Elevated Phenotypic Switching and Drug Resistance of <i>Candida albicans</i> from Human Immunodeficiency Virus-Positive Individuals prior to First Thrush Episode. Journal of Clinical Microbiology, 2000, 38, 3595-3607.	3.9	81
52	<i>In Vitro</i> Activity of a Novel Glucan Synthase Inhibitor, SCY-078, against Clinical Isolates of Candida auris. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	80
53	Characterization of biofilms formed by Candida parapsilosis, C. metapsilosis, and C. orthopsilosis. International Journal of Medical Microbiology, 2010, 300, 265-270.	3.6	77
54	Chromosome Loss Followed by Duplication Is the Major Mechanism of Spontaneous Mating-Type Locus Homozygosis in Candida albicans. Genetics, 2005, 169, 1311-1327.	2.9	76

#	Article	IF	CITATIONS
55	Passive Surveillance for Azole-Resistant <i>Aspergillus fumigatus</i> , United States, 2011–2013. Emerging Infectious Diseases, 2014, 20, 1498-1503.	4.3	76
56	Isolation of <i>Candida auris</i> from 9 patients in Central America: Importance of accurate diagnosis and susceptibility testing. Mycoses, 2018, 61, 44-47.	4.0	74
57	Cryptococcus gattii in the United States: Genotypic Diversity of Human and Veterinary Isolates. PLoS ONE, 2013, 8, e74737.	2.5	72
58	Recent Taxonomic Developments with Candida and Other Opportunistic Yeasts. Current Fungal Infection Reports, 2012, 6, 170-177.	2.6	69
59	Whole Genome Sequence Typing to Investigate the Apophysomyces Outbreak following a Tornado in Joplin, Missouri, 2011. PLoS ONE, 2012, 7, e49989.	2.5	66
60	Pharmacodynamic Optimization for Treatment of Invasive Candida auris Infection. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	65
61	Candida auris: A Review of Recommendations for Detection and Control in Healthcare Settings. Journal of Fungi (Basel, Switzerland), 2019, 5, 111.	3.5	64
62	Relationship between Switching and Mating in Candida albicans. Eukaryotic Cell, 2003, 2, 390-397.	3.4	63
63	Whole Genome Sequence Analysis of Cryptococcus gattii from the Pacific Northwest Reveals Unexpected Diversity. PLoS ONE, 2011, 6, e28550.	2.5	63
64	Trends in Antifungal Drug Susceptibility of Cryptococcus neoformans Isolates Obtained through Population-Based Surveillance in South Africa in 2002-2003 and 2007-2008. Antimicrobial Agents and Chemotherapy, 2011, 55, 2606-2611.	3.2	62
65	Detection of Fungal DNA in Human Body Fluids and Tissues during a Multistate Outbreak of Fungal Meningitis and Other Infections. Eukaryotic Cell, 2013, 12, 677-683.	3.4	62
66	<i>Notes from the Field:</i> Transmission of Pan-Resistant and Echinocandin-Resistant <i>Candida auris</i> in Health Care Facilities ― Texas and the District of Columbia, January–April 2021. Morbidity and Mortality Weekly Report, 2021, 70, 1022-1023.	15.1	62
67	Unique Aspects of Gene Expression during Candida albicans Mating and Possible G 1 Dependency. Eukaryotic Cell, 2005, 4, 1175-1190.	3.4	60
68	An environmental Sporothrix as a cause of corneal ulcer. Medical Mycology Case Reports, 2013, 2, 88-90.	1.3	59
69	The Investigational Fungal Cyp51 Inhibitor VT-1129 Demonstrates Potent <i>In Vitro</i> Activity against Cryptococcus neoformans and Cryptococcus gattii. Antimicrobial Agents and Chemotherapy, 2016, 60, 2528-2531.	3.2	58
70	<i>Candida albicans</i> Endocarditis Associated with a Contaminated Aortic Valve Allograft: Implications for Regulation of Allograft Processing. Clinical Infectious Diseases, 1998, 27, 688-691.	5.8	55
71	Increased Virulence and Competitive Advantage of a/α Over a/a or α/α Offspring Conserves the Mating System of Candida albicans. Genetics, 2005, 169, 1883-1890.	2.9	55
72	Current Epidemiology of Candida Infection. Clinical Microbiology Newsletter, 2014, 36, 131-136.	0.7	55

#	Article	IF	CITATIONS
73	Establishment and Use of Epidemiological Cutoff Values for Molds and Yeasts by Use of the Clinical and Laboratory Standards Institute M57 Standard. Journal of Clinical Microbiology, 2017, 55, 1262-1268.	3.9	55
74	Epidemiologic cutoff values for triazole drugs in Cryptococcus gattii: correlation of molecular type and in vitro susceptibility. Diagnostic Microbiology and Infectious Disease, 2012, 73, 144-148.	1.8	54
75	Hospital-Associated Multicenter Outbreak of Emerging Fungus <i>Candida auris</i> , Colombia, 2016. Emerging Infectious Diseases, 2019, 25, .	4.3	53
76	The Fungal Cyp51-Specific Inhibitor VT-1598 Demonstrates <i>In Vitro</i> and <i>In Vivo</i> Activity against Candida auris. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	53
77	Multilocus Sequence Type Analysis Reveals both Clonality and Recombination in Populations of Candida glabrata Bloodstream Isolates from U.S. Surveillance Studies. Eukaryotic Cell, 2010, 9, 619-625.	3.4	52
78	Whole-Genome Analysis of Exserohilum rostratum from an Outbreak of Fungal Meningitis and Other Infections. Journal of Clinical Microbiology, 2014, 52, 3216-3222.	3.9	52
79	Population Genetic Analysis Reveals a High Genetic Diversity in the Brazilian Cryptococcus gattii VGII Population and Shifts the Global Origin from the Amazon Rainforest to the Semi-arid Desert in the Northeast of Brazil. PLoS Neglected Tropical Diseases, 2016, 10, e0004885.	3.0	52
80	Comparison of In Vitro Susceptibility Characteristics of <i>Candida</i> Species from Cases of Invasive Candidiasis in Solid Organ and Stem Cell Transplant Recipients: Transplant-Associated Infections Surveillance Network (TRANSNET), 2001 to 2006. Journal of Clinical Microbiology, 2011, 49, 2404-2410.	3.9	51
81	Thinking beyond the Common Candida Species: Need for Species-Level Identification of Candida Due to the Emergence of Multidrug-Resistant Candida auris. Journal of Clinical Microbiology, 2017, 55, 3324-3327.	3.9	49
82	MLST and Whole-Genome-Based Population Analysis of Cryptococcus gattii VGIII Links Clinical, Veterinary and Environmental Strains, and Reveals Divergent Serotype Specific Sub-populations and Distant Ancestors. PLoS Neglected Tropical Diseases, 2016, 10, e0004861.	3.0	49
83	Activity of novel antifungal compound APX001A against a large collection of Candida auris. Journal of Antimicrobial Chemotherapy, 2018, 73, 3060-3062.	3.0	47
84	Identification of Candida auris by Use of the Updated Vitek 2 Yeast Identification System, Version 8.01: a Multilaboratory Evaluation Study. Journal of Clinical Microbiology, 2019, 57, .	3.9	47
85	Isolation of azole-resistant Aspergillus fumigatus from the environment in the south-eastern USA. Journal of Antimicrobial Chemotherapy, 2017, 72, 2443-2446.	3.0	46
86	Roles of TUP1 in Switching, Phase Maintenance, and Phase-Specific Gene Expression in Candida albicans. Eukaryotic Cell, 2002, 1, 353-365.	3.4	45
87	Exserohilum Infections Associated with Contaminated Steroid Injections. American Journal of Pathology, 2013, 183, 881-892.	3.8	45
88	Neonatal and Pediatric Candidemia: Results From Population-Based Active Laboratory Surveillance in Four US Locations, 2009–2015. Journal of the Pediatric Infectious Diseases Society, 2018, 7, e78-e85.	1.3	44
89	A Mycoses Study Group International Prospective Study of Phaeohyphomycosis: An Analysis of 99 Proven/Probable Cases. Open Forum Infectious Diseases, 2017, 4, ofx200.	0.9	43
90	Surveillance for azoles resistance in <i>Aspergillus</i> spp. highlights a high number of amphotericin Bâ€resistant isolates. Mycoses, 2018, 61, 360-365.	4.0	42

#	Article	IF	CITATIONS
91	Preliminary Laboratory Report of Fungal Infections Associated with Contaminated Methylprednisolone Injections. Journal of Clinical Microbiology, 2013, 51, 2654-2661.	3.9	41
92	Fungal Endophthalmitis Associated with Compounded Products. Emerging Infectious Diseases, 2014, 20, 248-256.	4.3	41
93	Development of a Luminex-Based Multiplex Assay for Detection of Mutations Conferring Resistance to Echinocandins in Candida glabrata. Journal of Clinical Microbiology, 2014, 52, 790-795.	3.9	41
94	Detection of TR ₃₄ /L98H <i>CYP51A</i> Mutation through Passive Surveillance for Azole-Resistant Aspergillus fumigatus in the United States from 2015 to 2017. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	40
95	Identification and Susceptibility Profile of <i>Candida fermentati</i> from a Worldwide Collection of <i>Candida guilliermondii</i> Clinical Isolates. Journal of Clinical Microbiology, 2009, 47, 242-244.	3.9	39
96	Fatal Disseminated Cryptococcus gattii Infection in New Mexico. PLoS ONE, 2011, 6, e28625.	2.5	38
97	Multilaboratory Testing of Two-Drug Combinations of Antifungals against <i>Candida albicans</i> , <i>Candida glabrata</i> , and <i>Candida parapsilosis</i> . Antimicrobial Agents and Chemotherapy, 2011, 55, 1543-1548.	3.2	38
98	Ibrexafungerp: A Novel Oral Triterpenoid Antifungal in Development for the Treatment of Candida auris Infections. Antibiotics, 2020, 9, 539.	3.7	38
99	Recognition of Diagnostic Gaps for Laboratory Diagnosis of Fungal Diseases: Expert Opinion from the Fungal Diagnostics Laboratories Consortium (FDLC). Journal of Clinical Microbiology, 2021, 59, e0178420.	3.9	38
100	Multidrug-Resistant <i>Aspergillus fumigatus</i> Carrying Mutations Linked to Environmental Fungicide Exposure — Three States, 2010–2017. Morbidity and Mortality Weekly Report, 2018, 67, 1064-1067.	15.1	38
101	<i>In Vitro</i> Activity of Ibrexafungerp, a Novel Glucan Synthase Inhibitor against Candida glabrata Isolates with <i>FKS</i> Mutations. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	37
102	Genotypes and population genetics of cryptococcus neoformans and cryptococcus gattii species complexes in Europe and the mediterranean area. Fungal Genetics and Biology, 2019, 129, 16-29.	2.1	37
103	Fluconazoleâ€ r esistant <i>Candida parapsilosis</i> strains with a Y132F substitution in the <i>ERG11</i> gene causing invasive infections in a neonatal unit, South Africa. Mycoses, 2020, 63, 471-477.	4.0	36
104	<i>In Vitro</i> Echinocandin Susceptibility of <i>Aspergillus</i> Isolates from Patients Enrolled in the Transplant-Associated Infection Surveillance Network. Antimicrobial Agents and Chemotherapy, 2011, 55, 3944-3946.	3.2	35
105	Multilocus sequence typing analysis reveals that Cryptococcus neoformans var. neoformans is a recombinant population. Fungal Genetics and Biology, 2016, 87, 22-29.	2.1	34
106	Detection of neonatal unit clusters of <i>Candida parapsilosis</i> fungaemia by microsatellite genotyping: Results from laboratoryâ€based sentinel surveillance, South Africa, 2009â€2010. Mycoses, 2017, 60, 320-327.	4.0	32
107	A highâ€ŧhroughput and rapid method for accurate identification of emerging multidrugâ€resistant Candida auris. Mycoses, 2019, 62, 513-518.	4.0	32
108	Notes from the Field: Surveillance for Candida auris — Colombia, September 2016–May 2017. Morbidity and Mortality Weekly Report, 2018, 67, 459-460.	15.1	30

#	Article	IF	CITATIONS
109	Candida auris: An Emerging Yeast Pathogen Posing Distinct Challenges for Laboratory Diagnostics, Treatment, and Infection Prevention. Archives of Pathology and Laboratory Medicine, 2020, 144, 107-114.	2.5	30
110	A MADS Box Protein Consensus Binding Site Is Necessary and Sufficient for Activation of the Opaque-Phase-Specific Gene OP4 of Candida albicans. Journal of Bacteriology, 1998, 180, 6607-6616.	2.2	29
111	Utility of a Luminex-based assay for multiplexed, rapid species identification of <i>Candida</i> isolates from an ongoing candidemia surveillance. Canadian Journal of Microbiology, 2010, 56, 348-351.	1.7	27
112	BD Phoenix and Vitek 2 Detection of <i>mecA</i> -Mediated Resistance in <i>Staphylococcus aureus</i> with Cefoxitin. Journal of Clinical Microbiology, 2009, 47, 2879-2882.	3.9	25
113	Investigating Fungal Outbreaks in the 21st Century. PLoS Pathogens, 2015, 11, e1004804.	4.7	25
114	Molecular characterization of C ryptococcus neoformans and C ryptococcus gattii from environmental sources and genetic comparison with clinical isolates in Apulia, Italy. Environmental Research, 2018, 160, 347-352.	7.5	24
115	Ceragenins are active against drug-resistant Candida auris clinical isolates in planktonic and biofilm forms. Journal of Antimicrobial Chemotherapy, 2018, 73, 1537-1545.	3.0	24
116	Understanding the Emergence of Multidrug-Resistant Candida: Using Whole-Genome Sequencing to Describe the Population Structure of Candida haemulonii Species Complex. Frontiers in Genetics, 2020, 11, 554.	2.3	24
117	Molecular Techniques for Genus and Species Determination of Fungi From Fresh and Paraffin-Embedded Formalin-Fixed Tissue in the Revised EORTC/MSGERC Definitions of Invasive Fungal Infection. Clinical Infectious Diseases, 2021, 72, S109-S113.	5.8	24
118	Cryptococcus gattii: An Emerging Fungal Pathogen in the Southeastern United States. American Journal of the Medical Sciences, 2012, 343, 510-511.	1.1	23
119	Detection of mucormycetes and other pathogenic fungi in formalin fixed paraffin embedded and fresh tissues using the extended region of 28S rDNA. Medical Mycology, 2016, 55, myw083.	0.7	23
120	Emerging Multidrug-Resistant Candida duobushaemulonii Infections in Panama Hospitals: Importance of Laboratory Surveillance and Accurate Identification. Journal of Clinical Microbiology, 2018, 56, .	3.9	22
121	Tools for Detecting a "Superbug― Updates on Candida auris Testing. Journal of Clinical Microbiology, 2022, 60, jcm0080821.	3.9	21
122	Genotyping of Candida parapsilosis from three neonatal intensive care units (NICUs) using a panel of five multilocus microsatellite markers: Broad genetic diversity and a cluster of related strains in one NICU. Infection, Genetics and Evolution, 2012, 12, 1654-1660.	2.3	20
123	Cryptococcus gattii, Florida, USA, 2011. Emerging Infectious Diseases, 2013, 19, 519-21.	4.3	20
124	Dating the Cryptococcus gattii Dispersal to the North American Pacific Northwest. MSphere, 2018, 3, .	2.9	20
125	Epidemiology of Echinocandin Resistance in Candida. Current Fungal Infection Reports, 2014, 8, 243-248.	2.6	19
126	In Vitro Activity of Novel Antifungal Olorofim against Filamentous Fungi and Comparison to Eight Other Antifungal Agents. Journal of Fungi (Basel, Switzerland), 2021, 7, 378.	3.5	19

#	Article	IF	CITATIONS
127	Screening of a Large Global <i>Aspergillus fumigatus</i> Species Complex Collection by Using a Species-Specific Microsphere-Based Luminex Assay. Journal of Clinical Microbiology, 2009, 47, 4171-4172.	3.9	18
128	Flucytosine resistance in <i>Cryptococcus gattii</i> is indirectly mediated by the FCY2-FCY1-FUR1 pathway. Medical Mycology, 2018, 56, 857-867.	0.7	18
129	Bloodstream Infections With <i>Candida auris</i> Among Children in Colombia: Clinical Characteristics and Outcomes of 34 Cases. Journal of the Pediatric Infectious Diseases Society, 2021, 10, 151-154.	1.3	18
130	Collateral consequences of agricultural fungicides on pathogenic yeasts: A One Health perspective to tackle azole resistance. Mycoses, 2022, 65, 303-311.	4.0	18
131	Antifungal activity of nikkomycin Z against <i>Candida auris</i> . Journal of Antimicrobial Chemotherapy, 2021, 76, 1495-1497.	3.0	17
132	Genomic Diversity of Azole-Resistant Aspergillus fumigatus in the United States. MBio, 2021, 12, e0180321.	4.1	17
133	Cluster ofCryptococcus neoformansInfections in Intensive Care Unit, Arkansas, USA, 2013. Emerging Infectious Diseases, 2015, 21, 1719-24.	4.3	16
134	Prolonged Incubation Period forCryptococcus gattiiInfection in Cat, Alaska, USA. Emerging Infectious Diseases, 2013, 19, 1034-1035.	4.3	14
135	Molecular typing of clinical and environmental isolates of <i>Cryptococcus gattii</i> species complex from southern California, United States. Mycoses, 2019, 62, 1029-1034.	4.0	14
136	Echinocandin resistance among Candida isolates at an academic medical centre 2005–15: analysis of trends and outcomes. Journal of Antimicrobial Chemotherapy, 2018, 73, 1677-1680.	3.0	13
137	Performance evaluation of fungal DNA PCR amplification from formalinâ€fixed paraffinâ€embedded tissue for diagnosis: Experience of a tertiary reference laboratory. Mycoses, 2021, 64, 603-611.	4.0	13
138	Whole-Genome Analysis of <i>Cryptococcus gattii</i> , Southeastern United States. Emerging Infectious Diseases, 2016, 22, 1098-1101.	4.3	12
139	Laboratoryâ€based surveillance of <i>Candida auris</i> in Colombia, 2016–2020. Mycoses, 2022, 65, 222-225.	4.0	12
140	Validation of 24-Hour Flucytosine MIC Determination by Comparison with 48-Hour Determination by the Clinical and Laboratory Standards Institute M27-A3 Broth Microdilution Reference Method. Journal of Clinical Microbiology, 2011, 49, 4322-4325.	3.9	11
141	Cryptococcus albidus Infection in a California Sea Lion (Zalophus californianus). Journal of Wildlife Diseases, 2012, 48, 1030-1034.	0.8	11
142	Use of Terbinafine in the Treatment Protocol of Intestinal Cryptococcus neoformans in a Dog. Journal of the American Animal Hospital Association, 2012, 48, 216-220.	1.1	11
143	Development and validation of benomyl birdseed agar for the isolation of Cryptococcus neoformans and Cryptococcus gattii from environmental samples. Medical Mycology, 2014, 52, 417-421.	0.7	11
144	Development of a Multilocus Sequence Typing System for Medically Relevant Bipolaris Species. Journal of Clinical Microbiology, 2015, 53, 3239-3246.	3.9	11

#	Article	IF	CITATIONS
145	Azole-Resistant Aspergillus fumigatus: What You Need To Know. Clinical Microbiology Newsletter, 2020, 42, 1-6.	0.7	11
146	Case–Case Comparison of Candida auris Versus Other Candida Species Bloodstream Infections: Results of an Outbreak Investigation in Colombia. Mycopathologia, 2020, 185, 917-923.	3.1	11
147	<i>Rhizopus microsporus</i> Infections Associated with Surgical Procedures, Argentina, 2006–2014. Emerging Infectious Diseases, 2020, 26, 937-944.	4.3	11
148	Identification of <i>Candida auris</i> and related species by multiplex PCR based on unique GPI proteinâ€encoding genes. Mycoses, 2021, 64, 194-202.	4.0	11
149	Emerging Fungal Infections in the Pacific Northwest: The Unrecognized Burden and Geographic Range of <i>Cryptococcus gattii</i> and <i>Coccidioides immitis</i> . Microbiology Spectrum, 2016, 4, .	3.0	11
150	Detection of Cryptococcus gattii in Selected Urban Parks of the Willamette Valley, Oregon. Mycopathologia, 2013, 175, 351-355.	3.1	10
151	Diagnostic Importance of Hyphae on Heart Valve Tissue in Histoplasma Endocarditis and Treatment With Isavuconazole. Open Forum Infectious Diseases, 2017, 4, ofx241.	0.9	10
152	Treatment Practices for Adults With Candidemia at 9 Active Surveillance Sites—United States, 2017–2018. Clinical Infectious Diseases, 2021, 73, 1609-1616.	5.8	10
153	Do Hospital Microbiology Laboratories Still Need To Distinguish Candida albicans from Candida dubliniensis?. Journal of Clinical Microbiology, 2011, 49, 4415-4415.	3.9	9
154	Candida glabrata: Multidrug Resistance and Increased Virulence in a Major Opportunistic Fungal Pathogen. Current Fungal Infection Reports, 2012, 6, 154-164.	2.6	8
155	Candida lusitaniae MICs to the echinocandins are elevated but FKS -mediated resistance is rare. Diagnostic Microbiology and Infectious Disease, 2016, 84, 52-54.	1.8	8
156	Cardiothoracic surgical site phaeohyphomycosis caused by <i>Bipolaris</i> mould, multiple US states, 2008–2013: a clinical description: Table 1 Medical Mycology, 2016, 54, 318-321.	0.7	8
157	Saksenaea vasiformis Orbital Cellulitis in an Immunocompetent Child Treated With Posaconazole. Journal of the Pediatric Infectious Diseases Society, 2018, 7, e169-e171.	1.3	8
158	Gene regulation in the white–opaque transition of <i>Candida albicans</i> . Canadian Journal of Botany, 1995, 73, 1049-1057.	1.1	7
159	Multilaboratory Testing of Antifungal Drug Combinations against Candida Species and Aspergillus fumigatus: Utility of 100 Percent Inhibition as the Endpoint. Antimicrobial Agents and Chemotherapy, 2015, 59, 1759-1766.	3.2	7
160	Prevalence of Candida auris in Canadian acute care hospitals among at-risk patients, 2018. Antimicrobial Resistance and Infection Control, 2020, 9, 82.	4.1	7
161	Clinical Characteristics, Healthcare Utilization, and Outcomes among Patients in a Pilot Surveillance System for Invasive Mold Disease—Georgia, United States, 2017–2019. Open Forum Infectious Diseases, 0, , .	0.9	7
162	Cryptococcus gattii Infections and Virulence. Current Fungal Infection Reports, 2014, 8, 81-89.	2.6	6

#	Article	IF	CITATIONS
163	Two cases of fungal keratitis caused by Metarhizium anisopliae. Medical Mycology Case Reports, 2018, 21, 8-11.	1.3	6
164	Acrophialophora levis brain abscess in a kidney transplant patient: A case report and review of the literature. Medical Mycology Case Reports, 2020, 28, 12-15.	1.3	6
165	Categorizing Susceptibility of Clinical Isolates of <i>Candida auris</i> to Amphotericin B, Caspofungin, and Fluconazole by Use of the CLSI M44-A2 Disk Diffusion Method. Journal of Clinical Microbiology, 2021, 59, .	3.9	6
166	Microbroth Dilution Susceptibility Testing of Candida species. Methods in Molecular Biology, 2016, 1356, 173-181.	0.9	6
167	An Invisible Threat: Mutation-Mediated Resistance to Triazole Drugs in Aspergillus. Current Fungal Infection Reports, 2012, 6, 288-295.	2.6	4
168	Talaromycosis (Penicilliosis) in a Cynomolgus Macaque. Veterinary Pathology, 2018, 55, 591-594.	1.7	4
169	Timing the Origin ofCryptococcus gattiisensu stricto, Southeastern United States. Emerging Infectious Diseases, 2018, 24, 2095-2097.	4.3	4
170	Ruptured mycotic aortic aneurysm in a sooty mangabey (Cercocebus atys). Comparative Medicine, 2011, 61, 532-7.	1.0	4
171	Mating and virulence of Candida albicans. The Mycologist, 2003, 17, 64-69.	0.4	3
172	Real-time PCR assays for genotyping of Cryptococcus gattii in North America. BMC Microbiology, 2014, 14, 125.	3.3	3
173	Bloodstream Infection Caused by Mucor velutinosus. Infectious Diseases in Clinical Practice, 2016, 24, e3-e4.	0.3	3
174	Innovative Approaches for Histoplasma Detection. Current Fungal Infection Reports, 2020, 14, 310-316.	2.6	3
175	Donorâ€derived Cryptococcus gattii sensu stricto infection in two kidney transplant recipients, southeastern United States. American Journal of Transplantation, 2021, 21, 3780-3784.	4.7	3
176	Cryptococcus gattii: Clinical Importance and Emergence in North America. Current Fungal Infection Reports, 2010, 4, 151-157.	2.6	2
177	Is This Zebra Really a Zebra? The Challenge of Diagnosing Rare Fungal Infections in Veterinary Pathology. Veterinary Pathology, 2019, 56, 510-511.	1.7	2
178	Antifungal Susceptibility Testing: The Times They Are A-Changing. Clinical Microbiology Newsletter, 2019, 41, 85-90.	0.7	2
179	Hot Topics in Antifungal Susceptibility Testing: a New Drug, a Bad Bug, Sweeping Caspofungin Testing under the Rug, and Solving the Epidemiological Cutoff Value Shrug. Clinical Microbiology Newsletter, 2016, 38, 103-108.	0.7	1
180	Emerging Fungal Infections in the Pacific Northwest: The Unrecognized Burden and Geographic Range of <i>Cryptococcus gattii</i> and <i>Coccidioides immitis</i> , 0, , 375-384.		0

#	Article	IF	CITATIONS
181	Antifungal Agents. , 0, , 2221-2235.		0